Contents

Search

VeriStrat testing

Indications: - non-small cell lung cancer without EGFR mutation - predicts response to EGFR tyrosine kinase inhibitors in patients who fail platinum-based chemotherapy Procedure: - multivariate proteomic test - results available within 72 hours

General

molecular diagnostic test

References

  1. Nelson R VeriStrat Testing Reduces Costs in NSCLC. Medscape - Apr 10, 2017. http://www.medscape.com/viewarticle/878395
  2. Akerley WL, Arnaud AM, Reddy B, Page RD Impact of a multivariate serum-based proteomic test on physician treatment recommendations for advanced non-small- cell lung cancer. Curr Med Res Opin. 2017 Mar 16:1-7 PMID: 28277859 http://www.tandfonline.com/doi/abs/10.1080/03007995.2017.1301903